ClinConnect ClinConnect Logo
Search / Trial NCT06624709

The Benefit in Terms of Improvement in Haemoglobin Level at 6 Months in Premature Babies Receiving Alternate Iron Substitution 4 Times a Week Compared to a Daily Substitution

Launched by RICCARDO PFISTER · Oct 2, 2024

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how different ways of giving iron supplements affect premature babies' health, specifically their hemoglobin levels and any abdominal discomfort they may feel. Hemoglobin is an important part of your blood that carries oxygen, and premature babies often have lower iron levels, which can lead to anemia (a condition where you don't have enough healthy red blood cells). In this study, researchers want to find out if giving iron four times a week is just as effective as giving it every day for improving hemoglobin levels, while also reducing tummy pain and making it easier for babies to take their medicine.

To be eligible for this trial, babies must be premature, born between 28 and 34 weeks of pregnancy, and at least two weeks old. Their parents will need to give consent for them to participate. This study aims to help improve the care of premature babies by comparing these two methods of iron supplementation. If your baby is selected for the trial, you will be a part of a group that monitors their health and any side effects to help find the best way to support their growth and development.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Premature babies between 28 0/7WA and 34 6/7 WA
  • Parental consent, postnatal
  • Age of 2 weeks
  • Exclusion Criteria:
  • anemia \< 80g/l at 2 weeks of age
  • Intraventricular Hemorrhage stage III and IV
  • Necrotizing Enterocolitis
  • Enteral feeding less than 100ml/kg/j after 2 weeks of life
  • Congenital disorder

About Riccardo Pfister

Riccardo Pfister is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous study design and adherence to ethical standards, Pfister collaborates with a diverse range of stakeholders, including healthcare professionals and regulatory bodies, to ensure the successful execution of clinical trials. His expertise spans multiple therapeutic areas, driving forward the development of new treatments while prioritizing patient safety and data integrity. Through a patient-centered approach, Riccardo Pfister aims to contribute significantly to the scientific community and enhance the landscape of healthcare.

Locations

Lausanne, Vd, Switzerland

Geneva, Ge, Switzerland

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported